PortfoliosLab logoPortfoliosLab logo
CCCC vs. BBOT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CCCC vs. BBOT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in C4 Therapeutics, Inc. (CCCC) and BridgeBio Oncology Therapeutics, Inc (BBOT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CCCC achieves a 120.94% return, which is significantly higher than BBOT's -40.10% return.


CCCC

1D
2.43%
1M
18.54%
YTD
120.94%
6M
108.91%
1Y
187.07%
3Y*
13.45%
5Y*
-35.32%
10Y*

BBOT

1D
-4.70%
1M
-12.28%
YTD
-40.10%
6M
-37.13%
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

CCCC vs. BBOT - Yearly Performance Comparison


2026 (YTD)2025
CCCC
C4 Therapeutics, Inc.
120.94%-21.07%
BBOT
BridgeBio Oncology Therapeutics, Inc
-40.10%22.75%

Correlation

The correlation between CCCC and BBOT is 0.26, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (All Time)
Calculated using the full available price history since Aug 12, 2025

0.26

Fundamentals

Market Cap

CCCC:

$532.03M

BBOT:

$600.24M

EPS

CCCC:

-$1.18

BBOT:

-$3.90

Total Revenue (TTM)

CCCC:

$28.71M

BBOT:

$0.00

Gross Profit (TTM)

CCCC:

$26.90M

BBOT:

-$194.00K

EBITDA (TTM)

CCCC:

-$107.31M

BBOT:

-$168.31M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CCCC vs. BBOT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CCCC
CCCC Risk / Return Rank: 8585
Overall Rank
CCCC Sharpe Ratio Rank: 8787
Sharpe Ratio Rank
CCCC Sortino Ratio Rank: 8888
Sortino Ratio Rank
CCCC Omega Ratio Rank: 8383
Omega Ratio Rank
CCCC Calmar Ratio Rank: 8787
Calmar Ratio Rank
CCCC Martin Ratio Rank: 8282
Martin Ratio Rank

BBOT

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CCCC vs. BBOT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for C4 Therapeutics, Inc. (CCCC) and BridgeBio Oncology Therapeutics, Inc (BBOT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CCCCBBOTDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.32

Calmar ratioReturn relative to maximum drawdown

3.61

Martin ratioReturn relative to average drawdown

7.01

CCCC vs. BBOT - Sharpe Ratio Comparison


Loading charts...

Drawdowns

CCCC vs. BBOT - Drawdown Comparison

The maximum CCCC drawdown since its inception was -97.82%, which is greater than BBOT's maximum drawdown of -48.14%. Use the drawdown chart below to compare losses from any high point for CCCC and BBOT.


Loading charts...

Drawdown Indicators


CCCCBBOTDifference

Max Drawdown

Largest peak-to-trough decline

-97.82%

-48.14%

-49.68%

Max Drawdown (1Y)

Largest decline over 1 year

-52.10%

Max Drawdown (3Y)

Largest decline over 3 years

-90.00%

Max Drawdown (5Y)

Largest decline over 5 years

-97.82%

Current Drawdown

Current decline from peak

-91.64%

-45.38%

-46.26%

Average Drawdown

Average peak-to-trough decline

-72.03%

-20.56%

-51.47%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.79%

Volatility

CCCC vs. BBOT - Volatility Comparison


Loading charts...

Volatility by Period


CCCCBBOTDifference

Volatility (1M)

Calculated over the trailing 1-month period

26.91%

Volatility (6M)

Calculated over the trailing 6-month period

63.00%

Volatility (1Y)

Calculated over the trailing 1-year period

100.81%

70.40%

+30.41%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

117.56%

70.40%

+47.16%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

112.81%

70.40%

+42.41%

Dividends

CCCC vs. BBOT - Dividend Comparison

Neither CCCC nor BBOT has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CCCC vs. BBOT - Financials Comparison

This section allows you to compare key financial metrics between C4 Therapeutics, Inc. and BridgeBio Oncology Therapeutics, Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M2022202320242025202600
(CCCC) Total Revenue
(BBOT) Total Revenue
Values in USD except per share items

Frequently Asked Questions


CCCC and BBOT have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for CCCC and BBOT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer